145 related articles for article (PubMed ID: 25323095)
1. Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.
Akhavan-Sigari R; Abili M; Gaab MR; Rohde V; Zafar N; Emami P; Ostertag H
Neurosurg Rev; 2015 Jan; 38(1):89-98; discussion 98-9. PubMed ID: 25323095
[TBL] [Abstract][Full Text] [Related]
2. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome.
de Castro CV; Guimaraes G; Aguiar S; Lopes A; Baiocchi G; da Cunha IW; Campos AH; Soares FA; Begnami MD
Hum Pathol; 2013 Sep; 44(9):1747-55. PubMed ID: 23618355
[TBL] [Abstract][Full Text] [Related]
4. Expression of PDGFR-α, EGFR and c-MET in spinal chordoma: a series of 52 patients.
Akhavan-Sigari R; Gaab MR; Rohde V; Abili M; Ostertag H
Anticancer Res; 2014 Feb; 34(2):623-30. PubMed ID: 24510991
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma.
Fasig JH; Dupont WD; LaFleur BJ; Olson SJ; Cates JM
Neuropathol Appl Neurobiol; 2008 Feb; 34(1):95-104. PubMed ID: 17973908
[TBL] [Abstract][Full Text] [Related]
6. Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.
Akhavan-Sigari R; Gaab MR; Rohde V; Brandis A; Tezval H; Abili M; von Eckardstein K; Ostertag H
Neurosurg Rev; 2014 Jan; 37(1):79-88. PubMed ID: 23999886
[TBL] [Abstract][Full Text] [Related]
7. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
Orzan F; Terreni MR; Longoni M; Boari N; Mortini P; Doglioni C; Riva P
Oncol Rep; 2007 Jul; 18(1):249-52. PubMed ID: 17549375
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.
Weinberger PM; Yu Z; Kowalski D; Joe J; Manger P; Psyrri A; Sasaki CT
Arch Otolaryngol Head Neck Surg; 2005 Aug; 131(8):707-11. PubMed ID: 16103303
[TBL] [Abstract][Full Text] [Related]
9. Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression.
Walter BA; Begnami M; Valera VA; Santi M; Rushing EJ; Quezado M
J Neurooncol; 2011 Jan; 101(2):199-206. PubMed ID: 20617367
[TBL] [Abstract][Full Text] [Related]
10. Expression of hepatocyte growth factor and c-MET in skull base chordoma.
Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A
Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912
[TBL] [Abstract][Full Text] [Related]
11. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
[TBL] [Abstract][Full Text] [Related]
12. Analysis of clinical factors and PDGFR-β in predicting prognosis of patients with clival chordoma.
Zhai Y; Bai J; Wang S; Gao H; Li M; Li C; Gui S; Zhang Y
J Neurosurg; 2018 Dec; 129(6):1429-1437. PubMed ID: 29303447
[TBL] [Abstract][Full Text] [Related]
13. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Luo P; Wang X; Zhou J; Li L; Jing Z
Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
[TBL] [Abstract][Full Text] [Related]
14. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M
J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer.
Yeh CY; Shin SM; Yeh HH; Wu TJ; Shin JW; Chang TY; Raghavaraju G; Lee CT; Chiang JH; Tseng VS; Lee YC; Shen CH; Chow NH; Liu HS
BMC Cancer; 2011 Apr; 11():139. PubMed ID: 21496277
[TBL] [Abstract][Full Text] [Related]
17. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.
Tamborini E; Virdis E; Negri T; Orsenigo M; Brich S; Conca E; Gronchi A; Stacchiotti S; Manenti G; Casali PG; Pierotti MA; Pilotti S
Neuro Oncol; 2010 Aug; 12(8):776-89. PubMed ID: 20164240
[TBL] [Abstract][Full Text] [Related]
18. Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma.
Lee DH; Zhang Y; Kassam AB; Park MJ; Gardner P; Prevedello D; Henry S; Horbinski C; Beumer JH; Tawbi H; Williams BJ; Shaffrey ME; Egorin MJ; Abounader R; Park DM
PLoS One; 2015; 10(8):e0134426. PubMed ID: 26247786
[TBL] [Abstract][Full Text] [Related]
19. Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas.
Wang K; Tian K; Wang L; Wu Z; Ren C; Hao S; Feng J; Li J; Wan H; Jia G; Zhang L; Zhang J
Mol Med Rep; 2015 Sep; 12(3):4298-4304. PubMed ID: 26099340
[TBL] [Abstract][Full Text] [Related]
20. Differences in Dural Penetration of Clival Chordomas Are Associated with Different Prognosis and Expression of Platelet-Derived Growth Factor Receptor-β.
Zhai Y; Bai J; Wang S; Du J; Wang J; Li C; Gui S; Zhang Y
World Neurosurg; 2017 Feb; 98():288-295. PubMed ID: 27506406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
